Scarica l'app Stockscreener
16.73
1.36%
-0.23
Precedente Chiudi:
$16.96
Aprire:
$17.21
Volume 24 ore:
368.89K
Relative Volume:
1.62
Capitalizzazione di mercato:
$557.24M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-13.17
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
+10.28%
1M Prestazione:
+2.83%
6M Prestazione:
+65.97%
1 anno Prestazione:
+39.30%
Intervallo 1D:
$15.98
$17.34
Intervallo di 1 settimana:
$15.34
$17.70
Portata 52W:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.73 | 564.90M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
Neurological Implants Market to Reach USD 12.39 Billion by 2031 | - openPR.com
NeuroPace (NASDAQ:NPCE) Shares Down 4.4%Should You Sell? - MarketBeat
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - ulpravda.ru
NeuroPace (NASDAQ:NPCE) Shapes Precision Neurological Care - Kalkine Media
How resilient is NeuroPace Inc. stock in market downturns2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - ulpravda.ru
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Neuropace, Inc. (NPCE) Stock Analysis: Uncovering an 18.90% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда
Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail
UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria
Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance
NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network
Neuropace files PMA supplement to FDA - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS - Business Wire
UBS Maintains NeuroPace (NPCE) Buy Recommendation - Nasdaq
UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World
NeuroPace price target raised to $20 from $18 at JPMorgan - MSN
Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com Australia
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.31%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):